Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: A Review of Recent Clinical Trials

Publisher： Bentham Science Publishers

E-ISSN： 1876-1038|2|2|117-120

ISSN： 1574-8871

Source： Reviews on Recent Clinical Trials, Vol.2, Iss.2, 2007-05, pp. : 117-120

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Advanced Non-Small Cell Lung Cancer

By  

Oncology, Vol. 91, Iss. 1, 2016-07 ,pp. : 26-34

Karger

Access to resources Recommend Favorite

Rebiopsy of non–small cell lung cancer patients with acquired resistance to epidermal growth factor receptor‐tyrosine kinase inhibitor

By  

CANCER, Vol. 119, Iss. 24, 2013-12 ,pp. : 4325-4332

John Wiley & Sons Inc

Access to resources Recommend Favorite

Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non‐small cell lung cancer

By  

CANCER, Vol. 120, Iss. 15, 2014-08 ,pp. : 2289-2298

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical Predictors of Response to EGFR Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Non-Small Cell Lung Cancer

By  

Oncology, Vol. 86, Iss. 2, 2014-01 ,pp. : 86-93

Karger

Access to resources Recommend Favorite

Epidermal Growth Factor Receptor Inhibition and Non-Small Cell Lung cancer

By von Eyben Finn  

Critical Reviews in Clinical Laboratory Sciences, Vol. 43, Iss. 4, 2006-08 ,pp. : 291-323

Informa Healthcare

Access to resources Recommend Favorite